Stock ADAG ADAGENE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Adagene Inc.

Equities

ADAG

US0053291078

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
2.8 USD +7.90% Intraday chart for Adagene Inc. +8.53% +44.97%
Mar. 29 Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 29 Adagene Inc. Announces Board Changes CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Adagene to Present at Investor Conferences in June
GL
Adagene : Entry into Sales Agreement - Form 6-K
PU
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
GL
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
GL
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
GL
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
AQ
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
GL
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
GL
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
AQ
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
GL
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
AQ
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
GL
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
AQ
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
GL
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
AQ
Adagene : Departure of Chief Technology Officer - Form 6-K
PU
Adagene to Present at Investor and Scientific Conferences in September
GL
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
AQ
Adagene : Anti-CTLA-4 Candidates Overview
PU
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ADAG Stock
  4. News Adagene Inc.
  5. Press Releases